#ASH24: Sanofi reveals positive Phase 3 data for BTK inhibitor from $3.7B Principia takeover

Sanofi’s BTK inhibitor rilzabrutinib helped 23% of adults with a rare autoimmune blood disorder achieve target platelet counts in a Phase 3 trial, compared to zero patients in the placebo arm, the company said Tuesday ...